Sotera Health Reports Q2 2024 Earnings
Intellectia.AI2024-08-06
Sotera Health Reports Q2 2024 Earnings
Sotera Health Company has released its financial results for the second quarter ending June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 | Q1 2024 | Q2 2023 | YoY Change (%) | QoQ Change (%) |
|---|---|---|---|---|---|
| Total Revenue | $276.6 million | $248.2 million | $255.3 million | 8.3% | 11.4% |
Interpretation: Sotera Health's total revenue for Q2 2024 increased by 8.3% year-over-year (YoY) and 11.4% quarter-over-quarter (QoQ). However, earnings per share (EPS) data and consensus estimates are not provided.
Revenue Performance by Segment
| Segment | Q2 2024 Revenue | Q2 2023 Revenue | YoY Change (%) |
|---|---|---|---|
| Sterigenics | $176.4 million | $166.6 million | 5.9% |
| Nordion | $41.2 million | $31.9 million | 29.0% |
| Nelson Labs | $59.0 million | $56.7 million | 4.0% |
Interpretation: The Sterigenics segment reported a 5.9% increase in revenue YoY, Nordion saw a significant 29.0% revenue increase, and Nelson Labs had a 4.0% rise in revenue YoY. Information for QoQ comparisons and revenue guidance is not provided.
Stock Price Movement
| Date of Earnings Release | Stock Price % Change Since Release |
|---|---|
| After event | +7.53% |
Interpretation: Following the earnings release, the company's stock price increased by approximately 7.53%.
Summary: Sotera Health reported a strong Q2 2024 with a notable increase in total revenue and significant growth in key segments, particularly Nordion. Despite lacking details on EPS, operational data, forward guidance, and commentary from officers, the company's stock responded positively, reflecting investor confidence.
Tesla's Robotaxi Launch Sparks New Market Momentum: What Investors Need to Know
Great News for Lucid Investors: Is Now the Time to Buy Lucid Stock?
Exploring IonQ Stock: Is This Quantum Computing Pioneer a Smart Investment?
Share